← Back to search
IDT BIOLOGIKA GMBH
DESSAU-ROSSLAU
UnclaimedClaim this profile (free)
Other Than Small Business
Prime contracting experience
6 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Prime | Department of Health and Human Services National Institutes of Health | CONTRACT #HHSN272201800011I IDT BIOLOGIKA FY21 PROCESS DEVELOPMENT AND MASTER BANK PRODUCTION FOR A STAPH AUREUS, SPA | 75N93018D00011USAspending | $883,131 | Sep 21, 2026 | Aug 19, 2021 – Apr 18, 2025 |
| Prime | Department of Health and Human Services National Institutes of Health | IDT BIOLOGIKA BASE AWARD FY20 MASTER CELL BANKS MANUFACTURING FOR PANDEMIC PREPAREDNESS COVID 19 CAN 844363 $20,462.00 | 75N93018D00011USAspending | $554,341 | Sep 23, 2025 | May 8, 2020 – May 17, 2025 |
| Prime | Department of Health and Human Services National Institutes of Health | MANUFACTURE OF INFLUENZA VIRUS HUMAN CHALLENGE MATERIAL FOR PHASE 1 AND 2. | 75N93018D00011USAspending | $4,154,750 | Aug 12, 2025 | Sep 26, 2023 – May 14, 2028 |
| Prime | Department of Health and Human Services National Institutes of Health | CONTRACT #HHSN272201800011I IDT BIOLOGIKA DEVELOPMENT AND MANUFACTURE OF TOXOID FUSION 3XSTAN12SMNLTR192GL211A AND CF,I,II,IV MASTER BANKS CAN 8470038 TOTAL $555,600.00 | 75N93018D00011USAspending | $1,209,261 | Apr 22, 2025 | Sep 17, 2020 – Apr 30, 2024 |
| Prime | Department of Health and Human Services National Institutes of Health | 1800011I IDT BIOLOGIKA VACCINE MANUFACTURING AND CHARACTERIZATION SERVICES TO VM19V8RDB--3 QUANTITY BASE AWARD IID CAN 8470036 $367,000.00 | 75N93018D00011USAspending | $2,723,700 | Apr 22, 2025 | Aug 19, 2019 – Apr 18, 2025 |
| Prime | Department of Health and Human Services National Institutes of Health | HHSN272201800011I IDT BIOLOGIKA MASTER CELL BANKS MANUFACTURING FOR NEXT GENERATION SARS-COV-2 VACCINES | 75N93018D00011USAspending | $2,623,000 | Apr 22, 2025 | May 15, 2018 – Apr 18, 2025 |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Subcontracting experience
1 record from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Subcontractor | Department of Health and Human Services | BASE PERIOD � IMMUNOGENICITY AND PRIMARY PLATFORM DEVELOPMENT
RABIES VIRUS BASED PLATFORM VACCINES. RABV CONSTRUCTS (FILORAB 1-3) EXPRESSING EBOV GP, SUDV GP OR MARV GP HAVE BEEN RECOVERED, CLONE PURIFIED AND MASTER VIRUS SEED (MVS) HAVE BEEN PREPARED.. THE GENE ENCODING LASV GPC HAS BEEN CLONED, INSERTED INTO THE RABV VECTOR AND SUCCESSFULLY RECOVERED IN VERO CELLS. CONTRACTOR SHALL CHARACTERIZE THE CDNA CLONES AND SHALL SEND TO SUBCONTRACTOR FOR GMP PRODUCTION OF MASTER SEED VIRUSES. THE CONTRACTOR SHALL PREPARE, INACTIVATE AND PURIFY FILORAB1 - 3 AND LASSARAB AT RESEARCH SCALE. CONTRACTOR SHALL USE THE PRODUCED VIRAL STOCKS FOR THE NHP IMMUNOGENICITY STUDIES. THE CONTRACTOR SHALL PROVIDE THE SUBCONTRACTOR WITH RESEARCH SCALE VIRAL STOCKS FOR FORMULATION STUDIES.
CONTRACTOR SHALL FILORAB1 DEVELOPMENT MATERIAL IS AVAILABLE FOR FORMULATION DEVELOPMENT AND NHP STUDIES.
CONTRACTOR SHALL ENSURE FILORAB2 DEVELOPMENT MATERIAL IS AVAILABLE FOR FORMULATION DEVELOPMENT AND NHP STUDIES.
CONTRACTOR SHALL ENSURE FILORAB3 DEVELOPMENT MATERIAL IS AVAILABLE FOR FORMULATION DEVELOPMENT AND NHP STUDIES.
CONTRACTOR SHALL ENSURE LASSARAB DEVELOPMENT MATERIAL IS AVAILABLE FOR FORMULATION DEVELOPMENT AND NHP STUDIES.
PREPARATION OF SEED LOT MATERIALS. CONTRACTOR SHALL PROVIDE THE MASTER CELL BANK FOR VERO CELLS. MASTER VIRUS BANKS FOR FILORAB 1 � 3 HAVE ALREADY BEEN PREPARED. CONTRACTOR SHALL PREPARE A MASTER VIRUS BANK FOR LASSARAB (BY RESCUE OF THE CDNA CLONE) UNDER GMP. CONTRACTOR SHALL ENSURE THAT THE LASSARAB BANK WILL BE PRODUCED.
CONTRACTOR SHALL COMMENCE PROJECT IMPLEMENTATION
CONTRACTOR SHALL PREPARE STARTING MATERIALS AND SEED BANKS.
PREPARATION OF NON-GMP LOT OF GLA-SE. CONTRACTOR SHALL PROVIDE GLA SALT AND SHALL PRODUCE AN ENGINEERING LOT OF GLA-SE. CONTRACTOR SHALL ENSURE THAT GLA-SE WILL BE PREPARED FOR PIVOTAL NHP IMMUNOGENICITY AND CHALLENGE STUDIES AND PIVOTAL GLP TOXICOLOGY STUDY.
CONTRACTOR SHALL CONDUCT BULK GLA SALT PRODUCTION.
CONTRACTOR SHALL CONDUCT GLA-SE LOT PRODUCTION.
CONTRACTOR SHALL CONDUCT LOT RELEASE TESTING.
IMMUNOGENICITY OF SINGLE, TRIVALENT, AND TETRAVALENT VACCINE IN NHPS. CONTRACTOR SHALL PERFORM AN NHP SAFETY AND IMMUNOGENICITY STUDY WITH LABORATORY RESEARCH VIRAL LOTS TO CONFIRM INDUCTION OF IMMUNE RESPONSES TO MONOVALENT FILORAB 1- 3 AND LASSARAB, THE TRIVALENT MIXTURE OF FILORAB1-3 AND THE TETRAVALENT FILORAB 1-3 AND LASSARAB VACCINE. THE CONTRACTOR SHALL PROVIDE STUDY PROTOCOLS TO NIAID FOR REVIEW BEFORE INITIATION OF THE STUDIES.
CONTRACTOR SHALL OBTAIN NIAID PROTOCOL REVIEW/APPROVAL AND SOURCING OF ANIMALS.
OPTION 1 � TESTING OF SEED LOT MATERIALS
TESTING OF SEED LOT MATERIALS. THE CONTRACTOR SHALL TEST EACH MASTER VIRUS SEED BANK OF FILORAB 1; 2; 3 AND LASSARAB FOR PURITY, CONTENT AND IDENTITY. CONTRACTOR WILL PROVIDE TEST PROTOCOLS TO NIAID FOR REVIEW BEFORE INITIATION OF THE STUDIES. THE TESTS WILL INCLUDE STERILITY, MYCOPLASMA TESTS, AND TESTS FOR OTHER EXTRANEOUS AGENTS TO MEET FDA TESTING REQUIREMENTS.
CONTRACTOR SHALL PERFORM TESTING OF MASTER VIRUS SEED BANK FILORAB 2, 3, AND LASSARAB ( SYN. BNSP333-GPLV).
CONTRACTOR SHALL PERFORM QUALIFICATION OF VERO WCB P 144 FOR DEVELOPMENT AND GMP MANUFACTURING.
DELIVERABLE � THE CONTRACTOR WILL ENSURE THAT QUALIFICATION OF ALL FOUR MASTER SEED BANKS IS COMPLETED AND WILL PROVIDE DOCUMENTATION OF TESTING RESULTS.
OPTION 3 � UPSTREAM AND DOWNSTREAM PROCESS DEVELOPMENT FOR MONOVALENT DRUG SUBSTANCE MANUFACTURE.
UPSTREAM AND DOWNSTREAM PROCESS DEVELOPMENT FOR MONOVALENT DRUG SUBSTANCE MANUFACTURE. UPSTREAM AND DOWNSTREAM PROCESSES HAVE BEEN WELL-DEFINED FOR FILORAB1 AND 2 BY THE CONTRACTOR. THE CONTRACTOR SHALL OPTIMIZE PROCESSES FOR THE
PRODUCTION OF FILORAB2, FILORAB3, AND LASSARAB, WITH ATTENTION TO THE VIRUS INACTIVATION STEPS AND GENERATION OF DRAFT BATCH RECORDS FOR PRODUCTION OF EACH MONOVALENT BULK DRUG PRODUCT.
PROCESS ENGINEERING
CONTRACTOR SHALL PERFORM OPTIMIZATION OF 080-03000-X158XX Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541712 Parent award performance state: PA Parent award description: IGF::OT::IGF ADVANCED DEVELOPMENT OF MULTIVALENT VACCINE CANDIDATES FOR FILOVIRUS AND LASSA FEVER View parent award on USAspending | — | $8,296,135 | May 21, 2025 | — – — |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Agencies supported
- Department of Health and Human ServicesGov-sourced
Government-sourced data comes from SAM.gov, SBA and USAspending.gov and is attributed to its source. Items marked company-reported were provided by the company and are verified by FedSub only where labeled. FedSub is a private company and is not affiliated with SBA, GSA/SAM.gov, or any government agency.